Your session is about to expire
← Back to Search
POEM-F for Achalasia
Study Summary
This trial aims to compare the efficacy of POEM-F vs POEM in reducing post-procedure GERD in achalasia patients, with experts from multiple countries participating. It could potentially replace conventional POEM as the preferred treatment for achalasia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does the study have an age restriction, and if so, what is it?
"According to the study's entry requirements, the minimum age of participants must be 18 and no older than 65."
Are enrollees being accepted for this clinical trial at present?
"Unfortunately, the details listed on clinicaltrials.gov indicate that this medical trial has stopped patient recruitment. Initially posted in November of 2023 and recently updated in September of 2023, there are nonetheless twenty other studies currently enrolling volunteers right now."
Has this research endeavor been implemented in numerous facilities across the US?
"At the present moment, this clinical trial has 7 active sites. These locations include Guangzhou, Hong Kong and Chandigarh in addition to 4 other spots. To minimize journey commitments, participants should aim to pick the closest site for enrollment."
To whom does this study render eligibility?
"This clinical trial is recruiting 81 adults aged 18-65 suffering from achalasia. Essential requirements to take part include having type I or II of the condition and either not receiving any prior treatment, or have unsuccessfully undertaken through-the-scope balloon dilation, Savary dilations, or pneumatic dilation."
Share this study with friends
Copy Link
Messenger